UPDATE: Jefferies Upgraded Charles River Laboratories to Buy on Tailwinds
Jefferies upgraded Charles River Laboratories (NYSE: CRL) from Hold to Buy and raised the price target from $41.00 to $50.00.
Jefferies commented, "We view CRL as the relative value Buy in CROs. Its business mix grows at a slower rate, but accelerating, R&D spending growth rebounds from its trough. Management is successfully broadening relationships to steepen the growth curve. We liken this to PRXL's aggressive move toward strategic deals in late-'09/'10, except that ED revenue converts much faster. Our survey shows ED spending normalizing, while pharma capacity declines."
Charles River Laboratories closed at $40.46 on Friday.
Latest Ratings for CRL
|Apr 2016||Gabelli & Co||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.